Skip to content

US · HKPD · MEDICAL - PHARMACEUTICALS

Cellyan Biotechnology Co., Ltd (HKPD) intrinsic value and stock valuation

$1.38as of 2026-11-21 · Mkt cap 4.5M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Cellyan Biotechnology Co., Ltd DCF and intrinsic value

InvestorsCraft values HKPD with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from HKPD’s statements →

Cellyan Biotechnology Co., Ltd Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Pharmaceuticals Yau Tong 999077 9zt.hk

How the business is doing

Fiscal 2023–2025, USD

Revenue
$20.3M
20232025
Net income
-$-30K
20232025
Free cash flow
$410K
20232025
Total equity
$4.99M
20232025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2023–2025, USD
202520242023
Revenue$20.3M$16.7M$12.6M
Operating income$130K$1.61M$1.04M
Net income-$-30K$1.33M$1M
EPSd-$-2.94K$180.5K$90.9K
Operating cash flow$570K-$-390K$1.73M
Capital expenditure-$-150K-$-90K-$-120K
Free cash flow$410K-$-480K$1.61M
Total assets$9.42M$8.67M$3.41M
Total debt$2.37M$2.09M$690K
Net debt$1.63M$1.47M$170K
Total equity$4.99M$4.25M$590K
Cash and short-term investments$3.01M$620K$520K
Income statement
202520242023
Revenue$20.3M$16.7M$12.6M
Cost of revenue$17.9M$13.1M$9.82M
Gross profit$2.42M$3.56M$2.74M
Research and development expenses$0.00$0.00$0.00
Selling, general and administrative expenses$2.22M$1.89M$1.76M
Other expenses$70K$60K-$-60K
Operating expenses$2.28M$1.95M$1.7M
Cost and expenses$20.2M$15.1M$11.5M
Interest income$0.00$0.00$0.00
Interest expense$100K$80K$20K
Depreciation and amortization$1.07M$930K$710K
Ebitda$1.21M$2.53M$1.76M
Operating income$130K$1.61M$1.04M
Total other income/expenses, net-$-100K-$-80K-$-20K
Income before tax$40K$1.53M$1.02M
Income tax expense$60K$200K$20K
Net income-$-30K$1.33M$1M
Weighted average shares outstanding$9.02M$7.37M$11M
Weighted average diluted shares outstanding$10.2M$7.37M$11M
Balance sheet
202520242023
Cash and short-term investments$3.01M$620K$520K
Net receivables$4.71M$3.72M$1.7M
Inventory$560K$930K$190K
Total current assets$8.73M$7.8M$2.75M
Property, plant and equipment, net$590K$830K$650K
Goodwill and intangible assets$100K$30K$0.00
Long-term investments$0.00$0.00$0.00
Total non-current assets$690K$870K$660K
Total assets$9.42M$8.67M$3.41M
Accounts payable$1.73M$1.32M$1.4M
Short-term debt$860K$850K$420K
Deferred revenue$120K$190K$270K
Total current liabilities$2.92M$3.18M$2.55M
Long-term debt$1.51M$1.24M$270K
Deferred revenue, non-current$0.00$0.00$0.00
Total non-current liabilities$1.51M$1.24M$270K
Capital lease obligations$500K$750K$510K
Total liabilities$4.43M$4.41M$2.82M
Common stock$10K$10K$10K
Retained earnings$1.5M$1.53M$200K
Accumulated other comprehensive income (loss)$10K-$0.00-$0.00
Total equity$4.99M$4.25M$590K
Total investments$2.26M$0.00$0.00
Total debt$2.37M$2.09M$690K
Net debt$1.63M$1.47M$170K
Cash flow statement
202520242023
Net income-$-30K$1.33M$1M
Depreciation and amortization$1.07M$930K$710K
Stock-based compensation$0.00$0.00$0.00
Change in working capital-$-520K-$-2.65M$10K
Accounts receivable-$-1.02M-$-2.09M-$-930K
Inventory$380K-$-740K-$-190K
Accounts payable$400K-$-110K$960K
Net cash provided by operating activities$570K-$-390K$1.73M
Investments in property, plant and equipment-$-70K-$-50K-$-110K
Acquisitions, net$0.00$0.00$0.00
Net cash used for investing activities-$-2.45M-$-40K-$-130K
Common stock issued$4.3M$510K$0.00
Common stock repurchased$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00
Net cash used for financing activities$2M$540K-$-1.16M
Net change in cash$120K$100K$440K
Cash at end of period$750K$630K$520K
Operating cash flow$570K-$-390K$1.73M
Capital expenditure-$-150K-$-90K-$-120K
Free cash flow$410K-$-480K$1.61M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Cellyan Biotechnology Co., Ltd

        Cellyan Biotechnology Co., Ltd, an investment holding entity, primarily operates within the over-the-counter (OTC) pharmaceutical sector, serving markets across Hong Kong and mainland China. The company's services encompass the international sourcing and distribution of OTC medications, alongside comprehensive e-commerce supply chain management. Furthermore, it provides essential logistical support, including customs clearance, drug registration, and warehousing facilities. Cellyan Biotechnology caters to a diverse clientele, which includes logistics partners for e-commerce platforms, various merchants, and pharmaceutical distributors. Founded in 2023, the company is based in Yau Tong, Hong Kong. It was formerly known as Hong Kong Pharma Digital Technology Holdings Limited and officially adopted the name Cellyan Biotechnology Co., Ltd in December 2025.

        CEO
        Chenyu Liang
        Employees
        27
        Beta
        2.48

        Explore

        Frequently asked questions

        What is the intrinsic value of Cellyan Biotechnology Co., Ltd (HKPD)?

        InvestorsCraft does not currently publish an intrinsic value for HKPD. How the IC value is calculated.

        Is HKPD undervalued?

        InvestorsCraft does not publish an undervaluation signal for HKPD at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.